Comparison of the effects of premedication with low-dose nalmesfene or remifentanil on the reduction of myofibrillation induced by etomidate

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033493

Enrollment

Unknown

Registered

2020-06-02

Start date

2020-06-10

Completion date

Unknown

Last updated

2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholelithiasis

Interventions

nalmefene group:Low-dose nalmefene

remifentanil group:Low-dose remifentanil

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Sixty patients with laparoscopic cholecystectomy due to cholelithiasis were selected, regardless of gender, ASA grade I-II, aged 20-50 years, and body mass index (BMI) 20-29 kg/?. The patient who signs the informed consent must be able to understand and be willing to participate in this study, and sign the informed consent at the same time.

Exclusion criteria

Exclusion criteria: Complicated with severe cardiopulmonary function and liver and kidney dysfunction, combined with hypertension, psychiatric disease, preoperative use of drugs that affect cardiovascular, and adrenal insufficiency.

Design outcomes

Primary

Measure	Time frame
Visual Analogue Scale/Score;vital signs;Muscle tremor;	—

Countries

China

Contacts

Public ContactGuofa Shan

Funing People's Hospital of Jiangsu Province

278189607@qq.com+86 13605101785

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026